A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults
Status:
COMPLETED
Trial end date:
2025-06-09
Target enrollment:
Participant gender:
Summary
This study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine. The flu portion will target multiple strains of the flu virus, while the COVID-19 part will focus on the spike protein of the SARS-CoV-2 virus. Both parts of this vaccine have been tested individually before. This will be the first study to test the combined vaccine in humans in healthy adult participants.